|
US6090382A
(en)
*
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
ATE239041T1
(de)
*
|
1996-02-09 |
2003-05-15 |
Basf Ag |
Humane antikörper welche an humanen tnfalpha binden
|
|
US20140186361A1
(en)
|
2012-09-07 |
2014-07-03 |
Coherus Biosciences, Inc. |
Stable Aqueous Formulations of Adalimumab
|
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US20090280065A1
(en)
*
|
2006-04-10 |
2009-11-12 |
Willian Mary K |
Uses and Compositions for Treatment of Psoriasis
|
|
US20040131614A1
(en)
*
|
2002-07-19 |
2004-07-08 |
Abbott Biotechnology Ltd. |
Treatment of pulmonary disorders using TNFalpha inhibitor
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US9415102B2
(en)
*
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
TWI439284B
(zh)
*
|
2004-04-09 |
2014-06-01 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
WO2006041970A2
(en)
*
|
2004-10-08 |
2006-04-20 |
Abbott Biotechnology Ltd. |
Treatment of respiratory syncytial virus (rsv) infection
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
JP5757495B2
(ja)
|
2005-05-16 |
2015-07-29 |
アッヴィ バイオテクノロジー リミテッド |
びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
|
|
TW201337266A
(zh)
|
2005-11-01 |
2013-09-16 |
Abbott Biotech Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
|
CN102391358B
(zh)
|
2006-04-05 |
2016-08-10 |
艾伯维生物技术有限公司 |
抗体纯化
|
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
|
US9605064B2
(en)
*
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
WO2007120626A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of ankylosing spondylitis
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
|
US20080311043A1
(en)
*
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
CN103316402A
(zh)
|
2006-06-30 |
2013-09-25 |
艾伯维生物技术有限公司 |
自动注射装置
|
|
EP2684895A1
(en)
|
2006-10-27 |
2014-01-15 |
AbbVie Biotechnology Ltd |
Crystalline anti-hTNFalpha antibodies
|
|
CA2681752A1
(en)
|
2007-03-29 |
2008-10-09 |
Abbott Laboratories |
Crystalline anti-human 1l-12 antibodies
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
CA2693771A1
(en)
*
|
2007-07-13 |
2009-01-22 |
Abbott Biotechnology Ltd. |
Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
|
|
MX2010001488A
(es)
|
2007-08-08 |
2010-03-01 |
Abbott Lab |
Composiciones y metodos para cristalizar anticuerpos.
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
US8420081B2
(en)
*
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
MX2010007393A
(es)
*
|
2008-01-03 |
2010-11-09 |
Abbott Biotech Ltd |
Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.
|
|
SG2013054218A
(en)
|
2008-01-15 |
2014-10-30 |
Abbott Gmbh & Co Kg |
Powdered protein compositions and methods of making same
|
|
AU2010242972B2
(en)
|
2009-04-29 |
2015-07-09 |
Abbvie Biotechnology Ltd |
Automatic injection device
|
|
EP2512558A4
(en)
|
2009-12-15 |
2014-08-13 |
Abbvie Biotechnology Ltd |
IMPROVED TRIP KNOB FOR AUTOMATIC INJECTION DEVICE
|
|
JP2013518590A
(ja)
|
2010-02-02 |
2013-05-23 |
アボツト・バイオテクノロジー・リミテツド |
ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
|
|
MX2012014080A
(es)
|
2010-06-03 |
2013-05-01 |
Abbvie Biotechnology Ltd |
Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
|
|
MX366337B
(es)
|
2010-10-06 |
2019-07-05 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
|
|
TWI603739B
(zh)
*
|
2010-11-11 |
2017-11-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
|
|
SG192119A1
(en)
|
2011-01-24 |
2013-08-30 |
Abbvie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
|
ES2734076T3
(es)
*
|
2011-02-17 |
2019-12-04 |
Kyowa Hakko Kirin Co Ltd |
Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada
|
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
UY34054A
(es)
*
|
2011-05-02 |
2012-11-30 |
Millennium Pharm Inc |
FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
|
|
GB201112429D0
(en)
*
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
|
WO2013096835A1
(en)
*
|
2011-12-23 |
2013-06-27 |
Abbvie Inc. |
Stable protein formulations
|
|
KR20160105535A
(ko)
|
2012-03-07 |
2016-09-06 |
카딜라 핼쓰캐어 리미티드 |
TNF-α 항체의 약제학적 제형
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
EP2863951A1
(en)
*
|
2012-06-12 |
2015-04-29 |
Boehringer Ingelheim International GmbH |
Pharmaceutical formulation for a therapeutic antibody
|
|
US8883979B2
(en)
*
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
HK1211981A1
(en)
|
2012-09-02 |
2016-06-03 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
ES2806946T3
(es)
*
|
2012-10-26 |
2021-02-19 |
Lupin Atlantis Holdings Sa |
Composición farmacéutica estable de la proteína de fusión TNFR:Fc etanercept
|
|
WO2014078627A1
(en)
*
|
2012-11-19 |
2014-05-22 |
Merck Sharp & Dohme Corp. |
Liquid formulations for tnfr:fc fusion proteins
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US9844594B2
(en)
|
2012-12-18 |
2017-12-19 |
Merck Sharp & Dohme Corp. |
Liquid formulations for an anti-TNF α antibody
|
|
CN102988984B
(zh)
*
|
2012-12-21 |
2015-05-20 |
嘉和生物药业有限公司 |
增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
|
|
WO2014114651A1
(en)
*
|
2013-01-24 |
2014-07-31 |
Glaxosmithkline Intellectual Property Development Limited |
Tnf-alpha antigen-binding proteins
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
|
UY35460A
(es)
*
|
2013-03-15 |
2014-10-31 |
Bayer Healthcare Llc |
Formulaciones de anticuerpos anti-receptor de prolactina
|
|
CN103446583B
(zh)
*
|
2013-03-21 |
2015-11-18 |
百奥泰生物科技(广州)有限公司 |
一种治疗TNF-α相关疾病的人抗体制剂
|
|
JP2014202667A
(ja)
*
|
2013-04-08 |
2014-10-27 |
株式会社島津製作所 |
抗体医薬用粒子径分布測定装置及び抗体医薬の粒子径分布測定方法
|
|
EP3003369A4
(en)
*
|
2013-05-28 |
2017-04-26 |
Momenta Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising pyrophosphate
|
|
ES2688726T5
(es)
*
|
2013-07-19 |
2022-06-27 |
Hexal Ag |
Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
AU2014337263B2
(en)
*
|
2013-10-16 |
2019-12-12 |
Outlook Therapeutics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
LT3060229T
(lt)
*
|
2013-10-24 |
2021-09-27 |
Astrazeneca Ab |
Stabilios vandeninės antikūno vaistinės formos
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
CN104666242B
(zh)
*
|
2013-11-26 |
2018-01-02 |
信达生物制药(苏州)有限公司 |
一种稳定的抗TNF‑α抗体制剂及其用途
|
|
WO2015080513A1
(en)
*
|
2013-11-29 |
2015-06-04 |
Hanwha Chemical Corporation |
A liquid formulation of a fusion protein comprising tnfr and fc region
|
|
CN104707146B
(zh)
*
|
2013-12-16 |
2019-04-16 |
浙江海正药业股份有限公司 |
一种含有阿达木单抗的药物组合物
|
|
EP3125923B1
(en)
*
|
2014-03-29 |
2024-10-16 |
Intas Pharmaceuticals Limited |
Lyophilized pharmaceutical composition of fc-peptide fusion protein
|
|
PL2946765T3
(pl)
*
|
2014-05-23 |
2017-08-31 |
Ares Trading S.A. |
Ciekła kompozycja farmaceutyczna
|
|
EP2946767B1
(en)
*
|
2014-05-23 |
2016-10-05 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP2946766B1
(en)
|
2014-05-23 |
2016-03-02 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
KR20170010003A
(ko)
*
|
2014-05-27 |
2017-01-25 |
아카데미아 시니카 |
박테로이드 기원의 푸코시다제 및 이의 사용 방법
|
|
KR20170018810A
(ko)
*
|
2014-06-10 |
2017-02-20 |
메이지 세이카 파루마 가부시키가이샤 |
안정한 아달리무맙 수성 제제
|
|
AR102198A1
(es)
*
|
2014-10-09 |
2017-02-08 |
Regeneron Pharma |
Proceso para reducir partículas subvisibles en una formulación farmacéutica
|
|
EP3247718B1
(en)
|
2015-01-21 |
2021-09-01 |
Outlook Therapeutics, Inc. |
Modulation of charge variants in a monoclonal antibody composition
|
|
EP3250598A1
(en)
*
|
2015-01-28 |
2017-12-06 |
Mabxience S.A. |
Pharmaceutical formulations for anti-tnf-alpha antibodies
|
|
EP3053572A1
(en)
*
|
2015-02-06 |
2016-08-10 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
EP3411401A1
(en)
*
|
2016-02-03 |
2018-12-12 |
Oncobiologics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
US11071782B2
(en)
|
2016-04-20 |
2021-07-27 |
Coherus Biosciences, Inc. |
Method of filling a container with no headspace
|
|
UA122610C2
(uk)
*
|
2016-06-30 |
2020-12-10 |
Селлтріон Інк. |
Стабільний рідкий фармацевтичний склад
|
|
AU2017312785B2
(en)
|
2016-08-16 |
2024-10-10 |
Regeneron Pharmaceuticals, Inc. |
Methods for quantitating individual antibodies from a mixture
|
|
KR102759512B1
(ko)
|
2016-10-25 |
2025-02-03 |
리제너론 파아마슈티컬스, 인크. |
크로마토그래피 데이터 분석을 위한 방법 및 시스템
|
|
RU2665966C2
(ru)
*
|
2016-12-30 |
2018-09-05 |
Закрытое Акционерное Общество "Биокад" |
Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
|
|
RU2764521C2
(ru)
*
|
2017-12-29 |
2022-01-18 |
Закрытое Акционерное Общество "Биокад" |
Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОа
|
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
|
EP3372242A1
(en)
*
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP3372241A1
(en)
*
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
KR20190130608A
(ko)
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CN110913906A
(zh)
|
2017-05-02 |
2020-03-24 |
默沙东公司 |
抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
|
|
CN107485713B
(zh)
*
|
2017-07-31 |
2018-08-28 |
百奥泰生物科技(广州)有限公司 |
针对TNF-α的抗体组合物及其应用
|
|
KR20190024572A
(ko)
*
|
2017-08-30 |
2019-03-08 |
(주)셀트리온 |
TNFα 관련 질환을 치료하기 위한 피하 투여 요법
|
|
WO2019060062A1
(en)
|
2017-09-19 |
2019-03-28 |
Regeneron Pharmaceuticals Inc. |
METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
|
|
PT3684407T
(pt)
|
2017-09-20 |
2026-03-30 |
Alvotech Hf |
Formulações farmacêuticas para adalimumab
|
|
EP3693001A4
(en)
|
2017-09-30 |
2021-07-07 |
Biocells (Beijing) Biotech Co., Ltd. |
PEPTIDIC COMPOSITION ALLOWING THE TREATMENT OF INJURIES RELATED TO EXCITING NEUROTOXICITY
|
|
BR112020019065A2
(pt)
*
|
2018-03-23 |
2020-12-29 |
AbbVie Deutschland GmbH & Co. KG |
Formulações de anticorpo anti-tau aquosas estáveis
|
|
EP3774894A1
(en)
*
|
2018-04-12 |
2021-02-17 |
Amgen Inc. |
Methods for making stable protein compositions
|
|
TWI919355B
(zh)
|
2018-07-02 |
2026-03-21 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
|
MX2021004356A
(es)
|
2018-10-18 |
2021-05-31 |
Merck Sharp & Dohme Llc |
Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
|
|
MA54089A
(fr)
|
2018-10-31 |
2022-02-09 |
Merck Sharp & Dohme |
Anticorps anti-pd-1 humain et procédés d'utilisation associés
|
|
JP7503056B6
(ja)
|
2018-11-07 |
2024-07-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
|
|
EA202192422A1
(ru)
|
2019-03-05 |
2021-12-09 |
Ридженерон Фармасьютикалз, Инк. |
Человеческий сывороточный альбумин в составах
|
|
CN113727730A
(zh)
*
|
2019-03-18 |
2021-11-30 |
阿尔沃科技Hf公司 |
高浓度TNFα抗体的含水制剂
|
|
WO2021234584A1
(en)
*
|
2020-05-21 |
2021-11-25 |
Shilpa Biologicals Private Limited |
Pharmaceutical compositions comprising adalimumab
|